MX365599B - Moleculas de transporte especificas de proteoglicano c4s. - Google Patents

Moleculas de transporte especificas de proteoglicano c4s.

Info

Publication number
MX365599B
MX365599B MX2015005867A MX2015005867A MX365599B MX 365599 B MX365599 B MX 365599B MX 2015005867 A MX2015005867 A MX 2015005867A MX 2015005867 A MX2015005867 A MX 2015005867A MX 365599 B MX365599 B MX 365599B
Authority
MX
Mexico
Prior art keywords
molecules
polypeptides
peptides
bam
compounds
Prior art date
Application number
MX2015005867A
Other languages
English (en)
Other versions
MX2015005867A (es
Inventor
Bonny Christophe
Chenaux Fabrice
Original Assignee
Phi Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phi Pharma Sa filed Critical Phi Pharma Sa
Publication of MX2015005867A publication Critical patent/MX2015005867A/es
Publication of MX365599B publication Critical patent/MX365599B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a moléculas aisladas, péptidos, y polipéptidos de secuencias o estructuras de consenso específicas, y a compuestos que comprenden o consisten de dichas moléculas, péptidos, y polipéptidos, que actúan como moléculas de transporte que específicamente reconocen proteoglicanos, condroitin-4-sulfato (C4S). Las moléculas aisladas, péptidos, polipéptidos, y compuestos de la invención pueden ser conjugados o de otra manera enlazados a una porción biológicamente activa (BAM). De esta forma los conjugados de BAM permiten la activación específica y suministro de la BAM, la cual puede ser, por ejemplo, un péptido, entidad química o ácido nucleico, en el citoplasma y/o núcleos de células que expresan C4S in vitro e in vivo.
MX2015005867A 2012-11-08 2013-11-07 Moleculas de transporte especificas de proteoglicano c4s. MX365599B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261723872P 2012-11-08 2012-11-08
EP12191840 2012-11-08
US201361763570P 2013-02-12 2013-02-12
EP13154867 2013-02-12
PCT/EP2013/073279 WO2014072411A1 (en) 2012-11-08 2013-11-07 C4s proteoglycan specific transporter molecules

Publications (2)

Publication Number Publication Date
MX2015005867A MX2015005867A (es) 2016-02-05
MX365599B true MX365599B (es) 2019-06-07

Family

ID=50684088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005867A MX365599B (es) 2012-11-08 2013-11-07 Moleculas de transporte especificas de proteoglicano c4s.

Country Status (11)

Country Link
US (1) US9688723B2 (es)
EP (1) EP2917227B1 (es)
JP (2) JP6595340B2 (es)
KR (1) KR102066768B1 (es)
CN (1) CN104903342B (es)
AU (1) AU2013343526B2 (es)
BR (1) BR112015010375B1 (es)
HK (1) HK1209437A1 (es)
IL (1) IL238428B (es)
MX (1) MX365599B (es)
WO (1) WO2014072411A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162285A1 (en) * 2014-04-25 2015-10-29 Phi Pharma Sa C6s specific transporter molecules
CN108794581B (zh) * 2018-06-26 2021-09-10 江苏大学 一种靶向结合淋巴癌细胞系的特异性d型多肽及其应用
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929464D0 (en) 1999-12-13 2000-02-09 Proteom Ltd Complementary peptide ligande generated from the human genome
US6693504B1 (en) 2000-01-11 2004-02-17 American Superconductor Corporation Internal support for superconductor windings
EP1572079A4 (en) 2002-03-29 2006-09-06 Centocor Inc MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES
US20050282755A1 (en) 2004-03-18 2005-12-22 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
US7317098B2 (en) 2004-07-01 2008-01-08 The Board Of Trustees Of Michigan State University Ryegrass CBF3 gene: identification and isolation
AU2005291231B2 (en) * 2004-10-05 2010-12-23 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
US8357365B2 (en) 2005-02-14 2013-01-22 The Regents Of The University Of California Granulysin peptides and methods of use thereof
WO2007079597A1 (en) * 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US8520747B2 (en) 2008-03-20 2013-08-27 Qualcomm Incorporated Channel estimation in wireless systems with impulsive interference
EP2303314B1 (en) 2008-06-25 2013-12-11 Braasch Biotech LLC Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof in cattle
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2012016595A1 (en) * 2010-08-05 2012-02-09 Polyphor Ag β-HAIRPIN PEPTIDOMIMETICS
KR102006036B1 (ko) 2011-05-24 2019-07-31 시믹 아이피, 엘엘씨 히알루론산-결합 합성 펩티도글리칸 및 이의 제조 및 이용 방법

Also Published As

Publication number Publication date
CN104903342B (zh) 2020-03-27
KR20150082411A (ko) 2015-07-15
HK1209437A1 (en) 2016-04-01
BR112015010375B1 (pt) 2023-03-28
CN104903342A (zh) 2015-09-09
BR112015010375A2 (es) 2017-08-22
WO2014072411A1 (en) 2014-05-15
IL238428B (en) 2019-07-31
US9688723B2 (en) 2017-06-27
JP6595340B2 (ja) 2019-10-23
AU2013343526B2 (en) 2019-09-12
WO2014072411A9 (en) 2014-07-03
EP2917227B1 (en) 2019-01-16
MX2015005867A (es) 2016-02-05
KR102066768B1 (ko) 2020-01-15
IL238428A0 (en) 2015-06-30
JP2019001814A (ja) 2019-01-10
US20150299253A1 (en) 2015-10-22
JP2015535299A (ja) 2015-12-10
EP2917227A1 (en) 2015-09-16
AU2013343526A2 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
CY1120560T1 (el) Βελτιστοποιημενο συστημα παραδοσης in vivo me ενδοσωματολυτικους παραγοντες για συζευγματα νουκλεϊνικου οξεος
MX346145B (es) Composición de sistema de suministro de arnsi in vivo basado en péptidos.
WO2012110636A3 (en) Carrier peptides for cell delivery
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
MX2012013375A (es) Peptido c pegilado.
MX2013002709A (es) Moleculas de union a 4-1bb.
WO2012012352A3 (en) Modified peptides and proteins
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2013036778A3 (en) Compstatin analogs with improved pharmacokinetic properties
BR112014000474A2 (pt) proteínas de fusão libertadoras de relaxina e suas utilizações
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
IN2012DN02981A (es)
WO2011157713A3 (en) Cell-penetrating peptides and uses therof
WO2012061443A3 (en) Compositions of a peptide targeting system for treating cancer
EA201201446A1 (ru) Пептидные производные, их получение и применение
WO2011071280A3 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
WO2011113027A3 (en) Npp1 fusion proteins
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
MX2013010392A (es) Proteinas de fusion npp1.
MX2014008373A (es) Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
IN2014CN04734A (es)
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
TR201901259T4 (tr) Karaciğere özgü tanı için hidrofobik modifiye peptidler.
MX2015005867A (es) Moleculas de transporte especificas de proteoglicano c4s.

Legal Events

Date Code Title Description
FG Grant or registration